213 related articles for article (PubMed ID: 27140664)
1. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.
Morad SA; Ryan TE; Neufer PD; Zeczycki TN; Davis TS; MacDougall MR; Fox TE; Tan SF; Feith DJ; Loughran TP; Kester M; Claxton DF; Barth BM; Deering TG; Cabot MC
J Lipid Res; 2016 Jul; 57(7):1231-42. PubMed ID: 27140664
[TBL] [Abstract][Full Text] [Related]
2. Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.
Morad SAF; MacDougall MR; Abdelmageed N; Kao LP; Feith DJ; Tan SF; Kester M; Loughran TP; Wang HG; Cabot MC
Exp Cell Res; 2019 Aug; 381(2):256-264. PubMed ID: 31112736
[TBL] [Abstract][Full Text] [Related]
3. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.
Morad SAF; Davis TS; MacDougall MR; Tan SF; Feith DJ; Desai DH; Amin SG; Kester M; Loughran TP; Cabot MC
Biochem Pharmacol; 2017 Apr; 130():21-33. PubMed ID: 28189725
[TBL] [Abstract][Full Text] [Related]
4. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.
Morad SA; Tan SF; Feith DJ; Kester M; Claxton DF; Loughran TP; Barth BM; Fox TE; Cabot MC
Biochim Biophys Acta; 2015 Jul; 1851(7):919-28. PubMed ID: 25769964
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.
Chapman JV; Gouazé-Andersson V; Messner MC; Flowers M; Karimi R; Kester M; Barth BM; Liu X; Liu YY; Giuliano AE; Cabot MC
Biochem Pharmacol; 2010 Aug; 80(3):308-15. PubMed ID: 20385104
[TBL] [Abstract][Full Text] [Related]
6. Ceramide-induced formation of ROS and ATP depletion trigger necrosis in lymphoid cells.
Villena J; Henriquez M; Torres V; Moraga F; Díaz-Elizondo J; Arredondo C; Chiong M; Olea-Azar C; Stutzin A; Lavandero S; Quest AF
Free Radic Biol Med; 2008 Mar; 44(6):1146-60. PubMed ID: 18191646
[TBL] [Abstract][Full Text] [Related]
7. Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Watters RJ; Fox TE; Tan SF; Shanmugavelandy S; Choby JE; Broeg K; Liao J; Kester M; Cabot MC; Loughran TP; Liu X
Leuk Lymphoma; 2013 Jun; 54(6):1288-96. PubMed ID: 23181473
[TBL] [Abstract][Full Text] [Related]
8. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth.
Flowers M; Fabriás G; Delgado A; Casas J; Abad JL; Cabot MC
Breast Cancer Res Treat; 2012 Jun; 133(2):447-58. PubMed ID: 21935601
[TBL] [Abstract][Full Text] [Related]
9. Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.
Morad SA; Levin JC; Shanmugavelandy SS; Kester M; Fabrias G; Bedia C; Cabot MC
Mol Cancer Ther; 2012 Nov; 11(11):2352-61. PubMed ID: 22962326
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.
Morad SA; Madigan JP; Levin JC; Abdelmageed N; Karimi R; Rosenberg DW; Kester M; Shanmugavelandy SS; Cabot MC
Biochem Pharmacol; 2013 Apr; 85(8):1057-65. PubMed ID: 23353700
[TBL] [Abstract][Full Text] [Related]
11. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells.
Cakir Z; Saydam G; Sahin F; Baran Y
J Cancer Res Clin Oncol; 2011 Feb; 137(2):279-86. PubMed ID: 20401667
[TBL] [Abstract][Full Text] [Related]
12. Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin.
Furlong SJ; Ridgway ND; Hoskin DW
Int J Oncol; 2008 Mar; 32(3):537-44. PubMed ID: 18292930
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.
Chapman JV; Gouazé-Andersson V; Karimi R; Messner MC; Cabot MC
Exp Cell Res; 2011 Jul; 317(12):1736-45. PubMed ID: 21396934
[TBL] [Abstract][Full Text] [Related]
14. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen.
Furlong SJ; Mader JS; Hoskin DW
Oncol Rep; 2006 May; 15(5):1385-90. PubMed ID: 16596215
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.
Morad SA; Davis TS; Kester M; Loughran TP; Cabot MC
Leuk Res; 2015 Oct; 39(10):1071-8. PubMed ID: 26220867
[TBL] [Abstract][Full Text] [Related]
16. Commitment to apoptosis by ceramides depends on mitochondrial respiratory function, cytochrome c release and caspase-3 activation in Hep-G2 cells.
Gentil B; Grimot F; Riva C
Mol Cell Biochem; 2003 Dec; 254(1-2):203-10. PubMed ID: 14674699
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Lysosomal Function Mitigates Protective Mitophagy and Augments Ceramide Nanoliposome-Induced Cell Death in Head and Neck Squamous Cell Carcinoma.
Shaw JJP; Boyer TL; Venner E; Beck PJ; Slamowitz T; Caste T; Hickman A; Raymond MH; Costa-Pinheiro P; Jameson MJ; Fox TE; Kester M
Mol Cancer Ther; 2020 Dec; 19(12):2621-2633. PubMed ID: 33087509
[TBL] [Abstract][Full Text] [Related]
18. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis.
Quillet-Mary A; Jaffrézou JP; Mansat V; Bordier C; Naval J; Laurent G
J Biol Chem; 1997 Aug; 272(34):21388-95. PubMed ID: 9261153
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial dysfunction links ceramide activated HRK expression and cell death.
Rizvi F; Heimann T; Herrnreiter A; O'Brien WJ
PLoS One; 2011 Mar; 6(3):e18137. PubMed ID: 21483866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
